Chapter/Section Purchase

1 Introduction to Research & Analysis Reports
1.1 Relapsed Acute Myeloid Leukemia Drug Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Relapsed Acute Myeloid Leukemia Drug Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Relapsed Acute Myeloid Leukemia Drug Overall Market Size
2.1 Global Relapsed Acute Myeloid Leukemia Drug Market Size: 2022 VS 2030
2.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue, Prospects & Forecasts: 2018-2030
2.3 Global Relapsed Acute Myeloid Leukemia Drug Sales: 2018-2030
3 Company Landscape
3.1 Top Relapsed Acute Myeloid Leukemia Drug Players in Global Market
3.2 Top Global Relapsed Acute Myeloid Leukemia Drug Companies Ranked by Revenue
3.3 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Companies
3.4 Global Relapsed Acute Myeloid Leukemia Drug Sales by Companies
3.5 Global Relapsed Acute Myeloid Leukemia Drug Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Relapsed Acute Myeloid Leukemia Drug Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Relapsed Acute Myeloid Leukemia Drug Product Type
3.8 Tier 1, Tier 2 and Tier 3 Relapsed Acute Myeloid Leukemia Drug Players in Global Market
3.8.1 List of Global Tier 1 Relapsed Acute Myeloid Leukemia Drug Companies
3.8.2 List of Global Tier 2 and Tier 3 Relapsed Acute Myeloid Leukemia Drug Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Relapsed Acute Myeloid Leukemia Drug Market Size Markets, 2022 & 2030
4.1.2 aNK Program
4.1.3 AT-9283
4.1.4 BI-836858
4.1.5 Binimetinib
4.1.6 BL-8040
4.1.7 Others
4.2 By Type - Global Relapsed Acute Myeloid Leukemia Drug Revenue & Forecasts
4.2.1 By Type - Global Relapsed Acute Myeloid Leukemia Drug Revenue, 2018-2023
4.2.2 By Type - Global Relapsed Acute Myeloid Leukemia Drug Revenue, 2024-2030
4.2.3 By Type - Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share, 2018-2030
4.3 By Type - Global Relapsed Acute Myeloid Leukemia Drug Sales & Forecasts
4.3.1 By Type - Global Relapsed Acute Myeloid Leukemia Drug Sales, 2018-2023
4.3.2 By Type - Global Relapsed Acute Myeloid Leukemia Drug Sales, 2024-2030
4.3.3 By Type - Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share, 2018-2030
4.4 By Type - Global Relapsed Acute Myeloid Leukemia Drug Price (Manufacturers Selling Prices), 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Relapsed Acute Myeloid Leukemia Drug Market Size, 2022 & 2030
5.1.2 Clinic
5.1.3 Hospital
5.1.4 Others
5.2 By Application - Global Relapsed Acute Myeloid Leukemia Drug Revenue & Forecasts
5.2.1 By Application - Global Relapsed Acute Myeloid Leukemia Drug Revenue, 2018-2023
5.2.2 By Application - Global Relapsed Acute Myeloid Leukemia Drug Revenue, 2024-2030
5.2.3 By Application - Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share, 2018-2030
5.3 By Application - Global Relapsed Acute Myeloid Leukemia Drug Sales & Forecasts
5.3.1 By Application - Global Relapsed Acute Myeloid Leukemia Drug Sales, 2018-2023
5.3.2 By Application - Global Relapsed Acute Myeloid Leukemia Drug Sales, 2024-2030
5.3.3 By Application - Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share, 2018-2030
5.4 By Application - Global Relapsed Acute Myeloid Leukemia Drug Price (Manufacturers Selling Prices), 2018-2030
6 Sights by Region
6.1 By Region - Global Relapsed Acute Myeloid Leukemia Drug Market Size, 2022 & 2030
6.2 By Region - Global Relapsed Acute Myeloid Leukemia Drug Revenue & Forecasts
6.2.1 By Region - Global Relapsed Acute Myeloid Leukemia Drug Revenue, 2018-2023
6.2.2 By Region - Global Relapsed Acute Myeloid Leukemia Drug Revenue, 2024-2030
6.2.3 By Region - Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share, 2018-2030
6.3 By Region - Global Relapsed Acute Myeloid Leukemia Drug Sales & Forecasts
6.3.1 By Region - Global Relapsed Acute Myeloid Leukemia Drug Sales, 2018-2023
6.3.2 By Region - Global Relapsed Acute Myeloid Leukemia Drug Sales, 2024-2030
6.3.3 By Region - Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share, 2018-2030
6.4 North America
6.4.1 By Country - North America Relapsed Acute Myeloid Leukemia Drug Revenue, 2018-2030
6.4.2 By Country - North America Relapsed Acute Myeloid Leukemia Drug Sales, 2018-2030
6.4.3 US Relapsed Acute Myeloid Leukemia Drug Market Size, 2018-2030
6.4.4 Canada Relapsed Acute Myeloid Leukemia Drug Market Size, 2018-2030
6.4.5 Mexico Relapsed Acute Myeloid Leukemia Drug Market Size, 2018-2030
6.5 Europe
6.5.1 By Country - Europe Relapsed Acute Myeloid Leukemia Drug Revenue, 2018-2030
6.5.2 By Country - Europe Relapsed Acute Myeloid Leukemia Drug Sales, 2018-2030
6.5.3 Germany Relapsed Acute Myeloid Leukemia Drug Market Size, 2018-2030
6.5.4 France Relapsed Acute Myeloid Leukemia Drug Market Size, 2018-2030
6.5.5 U.K. Relapsed Acute Myeloid Leukemia Drug Market Size, 2018-2030
6.5.6 Italy Relapsed Acute Myeloid Leukemia Drug Market Size, 2018-2030
6.5.7 Russia Relapsed Acute Myeloid Leukemia Drug Market Size, 2018-2030
6.5.8 Nordic Countries Relapsed Acute Myeloid Leukemia Drug Market Size, 2018-2030
6.5.9 Benelux Relapsed Acute Myeloid Leukemia Drug Market Size, 2018-2030
6.6 Asia
6.6.1 By Region - Asia Relapsed Acute Myeloid Leukemia Drug Revenue, 2018-2030
6.6.2 By Region - Asia Relapsed Acute Myeloid Leukemia Drug Sales, 2018-2030
6.6.3 China Relapsed Acute Myeloid Leukemia Drug Market Size, 2018-2030
6.6.4 Japan Relapsed Acute Myeloid Leukemia Drug Market Size, 2018-2030
6.6.5 South Korea Relapsed Acute Myeloid Leukemia Drug Market Size, 2018-2030
6.6.6 Southeast Asia Relapsed Acute Myeloid Leukemia Drug Market Size, 2018-2030
6.6.7 India Relapsed Acute Myeloid Leukemia Drug Market Size, 2018-2030
6.7 South America
6.7.1 By Country - South America Relapsed Acute Myeloid Leukemia Drug Revenue, 2018-2030
6.7.2 By Country - South America Relapsed Acute Myeloid Leukemia Drug Sales, 2018-2030
6.7.3 Brazil Relapsed Acute Myeloid Leukemia Drug Market Size, 2018-2030
6.7.4 Argentina Relapsed Acute Myeloid Leukemia Drug Market Size, 2018-2030
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Revenue, 2018-2030
6.8.2 By Country - Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Sales, 2018-2030
6.8.3 Turkey Relapsed Acute Myeloid Leukemia Drug Market Size, 2018-2030
6.8.4 Israel Relapsed Acute Myeloid Leukemia Drug Market Size, 2018-2030
6.8.5 Saudi Arabia Relapsed Acute Myeloid Leukemia Drug Market Size, 2018-2030
6.8.6 UAE Relapsed Acute Myeloid Leukemia Drug Market Size, 2018-2030
7 Manufacturers & Brands Profiles
7.1 4SC AG
7.1.1 4SC AG Company Summary
7.1.2 4SC AG Business Overview
7.1.3 4SC AG Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.1.4 4SC AG Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2018-2023)
7.1.5 4SC AG Key News & Latest Developments
7.2 AbbVie Inc.
7.2.1 AbbVie Inc. Company Summary
7.2.2 AbbVie Inc. Business Overview
7.2.3 AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.2.4 AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2018-2023)
7.2.5 AbbVie Inc. Key News & Latest Developments
7.3 Actinium Pharmaceuticals, Inc.
7.3.1 Actinium Pharmaceuticals, Inc. Company Summary
7.3.2 Actinium Pharmaceuticals, Inc. Business Overview
7.3.3 Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.3.4 Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2018-2023)
7.3.5 Actinium Pharmaceuticals, Inc. Key News & Latest Developments
7.4 Agios Pharmaceuticals, Inc.
7.4.1 Agios Pharmaceuticals, Inc. Company Summary
7.4.2 Agios Pharmaceuticals, Inc. Business Overview
7.4.3 Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.4.4 Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2018-2023)
7.4.5 Agios Pharmaceuticals, Inc. Key News & Latest Developments
7.5 Amgen Inc.
7.5.1 Amgen Inc. Company Summary
7.5.2 Amgen Inc. Business Overview
7.5.3 Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.5.4 Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2018-2023)
7.5.5 Amgen Inc. Key News & Latest Developments
7.6 Arog Pharmaceuticals, Inc.
7.6.1 Arog Pharmaceuticals, Inc. Company Summary
7.6.2 Arog Pharmaceuticals, Inc. Business Overview
7.6.3 Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.6.4 Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2018-2023)
7.6.5 Arog Pharmaceuticals, Inc. Key News & Latest Developments
7.7 Array BioPharma Inc.
7.7.1 Array BioPharma Inc. Company Summary
7.7.2 Array BioPharma Inc. Business Overview
7.7.3 Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.7.4 Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2018-2023)
7.7.5 Array BioPharma Inc. Key News & Latest Developments
7.8 Astellas Pharma Inc.
7.8.1 Astellas Pharma Inc. Company Summary
7.8.2 Astellas Pharma Inc. Business Overview
7.8.3 Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.8.4 Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2018-2023)
7.8.5 Astellas Pharma Inc. Key News & Latest Developments
7.9 Astex Pharmaceuticals, Inc.
7.9.1 Astex Pharmaceuticals, Inc. Company Summary
7.9.2 Astex Pharmaceuticals, Inc. Business Overview
7.9.3 Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.9.4 Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2018-2023)
7.9.5 Astex Pharmaceuticals, Inc. Key News & Latest Developments
7.10 AstraZeneca Plc
7.10.1 AstraZeneca Plc Company Summary
7.10.2 AstraZeneca Plc Business Overview
7.10.3 AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.10.4 AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2018-2023)
7.10.5 AstraZeneca Plc Key News & Latest Developments
7.11 AVEO Pharmaceuticals, Inc.
7.11.1 AVEO Pharmaceuticals, Inc. Company Summary
7.11.2 AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Business Overview
7.11.3 AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.11.4 AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2018-2023)
7.11.5 AVEO Pharmaceuticals, Inc. Key News & Latest Developments
7.12 BioLineRx, Ltd.
7.12.1 BioLineRx, Ltd. Company Summary
7.12.2 BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Business Overview
7.12.3 BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.12.4 BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2018-2023)
7.12.5 BioLineRx, Ltd. Key News & Latest Developments
7.13 Boehringer Ingelheim GmbH
7.13.1 Boehringer Ingelheim GmbH Company Summary
7.13.2 Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Business Overview
7.13.3 Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.13.4 Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2018-2023)
7.13.5 Boehringer Ingelheim GmbH Key News & Latest Developments
7.14 Boston Biomedical, Inc.
7.14.1 Boston Biomedical, Inc. Company Summary
7.14.2 Boston Biomedical, Inc. Business Overview
7.14.3 Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.14.4 Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2018-2023)
7.14.5 Boston Biomedical, Inc. Key News & Latest Developments
7.15 Bristol-Myers Squibb Company
7.15.1 Bristol-Myers Squibb Company Company Summary
7.15.2 Bristol-Myers Squibb Company Business Overview
7.15.3 Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.15.4 Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2018-2023)
7.15.5 Bristol-Myers Squibb Company Key News & Latest Developments
7.16 Calithera Biosciences, Inc.
7.16.1 Calithera Biosciences, Inc. Company Summary
7.16.2 Calithera Biosciences, Inc. Business Overview
7.16.3 Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.16.4 Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2018-2023)
7.16.5 Calithera Biosciences, Inc. Key News & Latest Developments
7.17 Celgene Corporation
7.17.1 Celgene Corporation Company Summary
7.17.2 Celgene Corporation Business Overview
7.17.3 Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.17.4 Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2018-2023)
7.17.5 Celgene Corporation Key News & Latest Developments
7.18 Cornerstone Pharmaceuticals, Inc.
7.18.1 Cornerstone Pharmaceuticals, Inc. Company Summary
7.18.2 Cornerstone Pharmaceuticals, Inc. Business Overview
7.18.3 Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.18.4 Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2018-2023)
7.18.5 Cornerstone Pharmaceuticals, Inc. Key News & Latest Developments
7.19 CTI BioPharma Corp.
7.19.1 CTI BioPharma Corp. Company Summary
7.19.2 CTI BioPharma Corp. Business Overview
7.19.3 CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.19.4 CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2018-2023)
7.19.5 CTI BioPharma Corp. Key News & Latest Developments
8 Global Relapsed Acute Myeloid Leukemia Drug Production Capacity, Analysis
8.1 Global Relapsed Acute Myeloid Leukemia Drug Production Capacity, 2018-2030
8.2 Relapsed Acute Myeloid Leukemia Drug Production Capacity of Key Manufacturers in Global Market
8.3 Global Relapsed Acute Myeloid Leukemia Drug Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Relapsed Acute Myeloid Leukemia Drug Supply Chain Analysis
10.1 Relapsed Acute Myeloid Leukemia Drug Industry Value Chain
10.2 Relapsed Acute Myeloid Leukemia Drug Upstream Market
10.3 Relapsed Acute Myeloid Leukemia Drug Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Relapsed Acute Myeloid Leukemia Drug Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer